Skip to main content

Advertisement

SpringerLink
Log in

Clinical Significance of Cytological Status of Peritoneal Lavage Fluid During Intraperitoneal Chemotherapy for Gastric Cancer with Overt Peritoneal Dissemination

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

A positive cytology of peritoneal lavage fluid (CY1) is a poor prognostic factor in patients with gastric cancer (GC). We have recently reported that CY1 often changes to negative (CY0) following combination chemotherapy including intraperitoneal (IP) paclitaxel (PTX), which results in marked prolongation of survival in GC patients with peritoneal dissemination (P1).

Methods

A total of 95 P1 GC patients who received combination chemotherapy with S-1 and intravenous and IP PTX were enrolled. Peritoneal lavage fluid was periodically examined cytologically at the start of every cycle of chemotherapy, and the impact of CY status on patient outcome was retrospectively evaluated.

Results

Seventy-three (76.8 %) of 95 patients were diagnosed as CY1 before initial treatment. Median survival time (MST) of the CY1 group was significantly shorter than that of the CY0 group (19.1 vs. 32.5 months, P = 0.033). Cytological status changed from CY1 to CY0 in 68 (93.2 %) of 73 CY1 patients during the whole treatment period and MST of patients who showed a negative change was significantly longer than that of the unchanged group (20.0 vs. 13.0 months, P = 0.0017). In 64 patients who achieved CY0 by IP PTX regimen, the median time to achieve CY0 was 1.4 months, and patients who achieved a negative change within 1 month showed a particularly good outcome (MST = 26.1 months).

Conclusions

Periodic cytological examination of peritoneal lavage fluid is clinically useful to evaluate the efficacy of treatment as well as to predict the outcome of patients with P1 GC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Brigand C, Arvieux C, Gilly FN, Glehen O. Treatment of peritoneal carcinomatosis in gastric cancers. Dig Dis. 2004;22(4):366-73.

    Article  CAS  PubMed  Google Scholar 

  2. Isobe Y, Nashimoto A, Akazawa K, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer. 2011;14(4):301-16.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Matharu G, Tucker O, Alderson D. Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg. 2011;98(9):1225-35.

    Article  CAS  PubMed  Google Scholar 

  4. Yonemura Y, Elnemr A, Endou Y, et al. Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012;2012:148420.

    PubMed Central  PubMed  Google Scholar 

  5. Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12-26.

    Article  CAS  PubMed  Google Scholar 

  6. Kitayama J. Intraperitoneal chemotherapy against peritoneal carcinomatosis: Current status and future perspective. Surg Oncol. 27 2014;23(2):99–106.

    Article  PubMed  Google Scholar 

  7. Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol. 2010;17(12):3173-3180.

    Article  PubMed  Google Scholar 

  8. La Torre M, Ferri M, Giovagnoli MR, et al. Peritoneal wash cytology in gastric carcinoma. Prognostic significance and therapeutic consequences. Eur J Surg Oncol. 2010;36(10):982-986.

    Article  PubMed  Google Scholar 

  9. Lee SD, Ryu KW, Eom BW, Lee JH, Kook MC, Kim YW. Prognostic significance of peritoneal washing cytology in patients with gastric cancer. Br J Surg. 2012;99(3):397-403.

    Article  CAS  PubMed  Google Scholar 

  10. Sobin LG. TNM classification of malignant tumours, 7th edn. New York: Wiley; 2009.

    Google Scholar 

  11. Association JGC. Japanese classification of gastric carcinoma, 3rd English edn. Gastric Cancer. 2011;14(2):101-12.

    Article  Google Scholar 

  12. Yonemura Y, Bandou E, Sawa T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32(6):661-5.

    Article  CAS  PubMed  Google Scholar 

  13. Fushida S, Kinoshita J, Yagi Y, et al. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep. 2008;19(5):1305-10.

    CAS  PubMed  Google Scholar 

  14. Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol. 2009;100(4):311-6.

    Article  CAS  PubMed  Google Scholar 

  15. Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):67-70.

    Article  CAS  PubMed  Google Scholar 

  16. Fujiwara Y, Takiguchi S, Nakajima K, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol. 2011;18(13):3726-31.

    Article  PubMed  Google Scholar 

  17. Fujiwara Y, Takiguchi S, Nakajima K, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105(1):38-42.

    Article  CAS  PubMed  Google Scholar 

  18. Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119(18):3354-8.

    Article  CAS  PubMed  Google Scholar 

  19. Lorenzen S, Panzram B, Rosenberg R, et al. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol. 2010;17(10):2733-9.

    Article  PubMed  Google Scholar 

  20. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma—2nd English Edition. Gastric Cancer 1998;1:10–24.

    Article  PubMed  Google Scholar 

  21. Ishigami H, Kitayama J, Otani K, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009;76(5):311-4.

    Article  CAS  PubMed  Google Scholar 

  22. Emoto S, Ishigami H, Hidemura A, et al. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Jpn J Clin Oncol. 2012;42(11):1013-9.

    Article  PubMed  Google Scholar 

  23. Kitayama J, Ishigami H, Yamaguchi H, et al. Salvage Gastrectomy After Intravenous and Intraperitoneal Paclitaxel (PTX) Administration with Oral S-1 for Peritoneal Dissemination of Advanced Gastric Cancer with Malignant Ascites. Ann Surg Oncol. 2014;21(2):539-46.

    Article  PubMed  Google Scholar 

  24. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315-21.

    Article  CAS  PubMed  Google Scholar 

  25. Katsuragi K, Yashiro M, Sawada T, Osaka H, Ohira M, Hirakawa K. Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. Br J Cancer. 2007;97(4):550-6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Cotte E, Peyrat P, Piaton E, et al. Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study. Eur J Surg Oncol. 2013;39(7):707-14.

    Article  CAS  PubMed  Google Scholar 

  27. Leake PA, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S27-37.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This work was funded by the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Ministry of Health, Labor and Welfare of Japan, and by a grant-in-aid of the Public Trust Surgery Research Fund, Tokyo, Japan. We thank Ms. I. Nieda for her clerical work.

Funding

This work was funded by the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Ministry of Health, Labor and Welfare of Japan, and by a grant-in-aid of the Public Trust Surgery Research Fund, Tokyo, Japan.

Disclosures

The authors have no financial disclosure.

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan

    Shigenobu Emoto MD, Joji Kitayama MD, Hironori Ishigami MD, Hironori Yamaguchi MD & Toshiaki Watanabe MD

Authors
  1. Shigenobu Emoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joji Kitayama MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hironori Ishigami MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hironori Yamaguchi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshiaki Watanabe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joji Kitayama MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Emoto, S., Kitayama, J., Ishigami, H. et al. Clinical Significance of Cytological Status of Peritoneal Lavage Fluid During Intraperitoneal Chemotherapy for Gastric Cancer with Overt Peritoneal Dissemination. Ann Surg Oncol 22, 780–786 (2015). https://doi.org/10.1245/s10434-014-4082-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4082-y

Keywords

Search

Navigation